Moolec Science SA
$7.28
▲
10.41%
2026-04-21 08:11:00
www.moolecscience.com
NCM: MLEC
Explore Moolec Science SA stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.29 M
Current Price
$7.28
52W High / Low
$157.05 / $3.07
Stock P/E
—
Book Value
$0.7
Dividend Yield
—
ROCE
11.2%
ROE
344.24%
Face Value
—
EPS
$-258.69
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
—
Debt / Equity
-3.74
Current Ratio
0.13
Quick Ratio
0.12
Forward P/E
-29.63
Price / Sales
—
Enterprise Value
—
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Caribou Biosciences, Inc. | $2.29 | — | $212.6 M | — | -90.82% | -78.97% | $3.54 / $0.71 | $1.28 |
| 2. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
| 3. | enGene Therapeutics Inc. | $8.53 | — | $571.42 M | — | -65% | -46.07% | $12.25 / $2.65 | $4.2 |
| 4. | Palatin Technologies, Inc. | $22.07 | — | $39.22 M | — | 478.76% | -3.79% | $31 / $2 | $6.53 |
| 5. | Bone Biologics Corporation | $1.38 | — | $2.5 M | — | -60.16% | -70.17% | $6.75 / $1.05 | $3 |
| 6. | OKYO Pharma Limited | $1.59 | — | $85.27 M | — | 127.79% | 82.36% | $3.35 / $1.11 | $-0.09 |
| 7. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
Quarterly Results
Figures shown in M / B
| Q4 2024 | Q3 2024 | |
|---|---|---|
| Sales | 2.64 M | 1.56 M |
| Operating Profit | -2.06 M | -2.1 M |
| Net Profit | -2.43 M | -1.92 M |
| EPS in Rs | -3.34 | -2.64 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 333.61 M | 466.38 M | 420.87 M | 0 M |
| Operating Profit | -3.51 M | 41.76 M | 50.61 M | -3.65 M |
| Net Profit | -111.46 M | -32.69 M | 40.44 M | -4.53 M |
| EPS in Rs | -153.5 | -45.01 | 55.69 | -6.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 204.71 M | 949.84 M | 24.05 M | 5.69 M |
| Total Liabilities | 287.58 M | 699.84 M | 13.95 M | 4.09 M |
| Equity | -65.97 M | 1.21 M | 10.11 M | 1.6 M |
| Current Assets | 31.19 M | 438.21 M | 5.33 M | 1.08 M |
| Current Liabilities | 236.05 M | 427.4 M | 12.6 M | 4.09 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 3.64 M | 39.56 M | -41.16 M | -1.89 M |
| Investing CF | -35.99 M | -27.4 M | -25.59 M | 0 M |
| Financing CF | -15.02 M | -1.49 M | 76.22 M | 2 M |
| Free CF | -10.98 M | 14.53 M | -64.09 M | -1.89 M |
| Capex | -14.62 M | -25.03 M | -22.93 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -28.47% | 10.81% | — | — |
| Earnings Growth % | -241.01% | -180.83% | 993.24% | — |
| Profit Margin % | -33.41% | -7.01% | 9.61% | — |
| Operating Margin % | -1.05% | 8.96% | 12.02% | — |
| Gross Margin % | 37.69% | 38.45% | 42.58% | — |
| EBITDA Margin % | -32.87% | 6.25% | 23.97% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-05 | 1:0.0666667 |
| 2025-05-14 | 1:0.1 |